Khan, S.; Cao, L.; Wiegand, J.; Zhang, P.; Zajac-Kaye, M.; Kaye, F.J.; Zheng, G.; Zhou, D.
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells 2024, 13, 528.
https://doi.org/10.3390/cells13060528
AMA Style
Khan S, Cao L, Wiegand J, Zhang P, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D.
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells. 2024; 13(6):528.
https://doi.org/10.3390/cells13060528
Chicago/Turabian Style
Khan, Sajid, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, and Daohong Zhou.
2024. "PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer" Cells 13, no. 6: 528.
https://doi.org/10.3390/cells13060528
APA Style
Khan, S., Cao, L., Wiegand, J., Zhang, P., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D.
(2024). PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells, 13(6), 528.
https://doi.org/10.3390/cells13060528